Drug Trial Radar · NCT02137772
Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)
Last checked: Nov 20, 2026Latest source record: Sep 11, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
570
Actual
Start
Jun 6, 2014
Primary completion
Aug 8, 2016
Study completion Nov 21, 2016
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 14, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study evaluated the efficacy and safety of letermovir (MK-8228) for the prevention of clinically-significant CMV infection in adult, CMV-seropositive recipients of allogeneic hematopoietic stem cell transplant (HSCT). The hypothesis being tested was that MK-8228 is superior to placebo in the prevention of clinically-significant CMV infection through Week 24 post-transplant.
Conditions
- Prevention of CMV Infection or Disease
Interventions
LetermovirDrug
Letermovir 240 mg / 480 mg tablets, or 240 mg / 480 mg intravenous solution in 250 mL to be infused over 60 minutes.
PlaceboDrug
Placebo tablets, or intravenous solution in 250 mL to be infused over 60 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Clinically-significant CMV Infection up to Week 24 Post-transplantTime frame: Up to Week 24 post-transplant
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.